Truist downgraded Iovance Biotherapeutics (IOVA) to Hold from Buy without a price target The firm wants Iovance to get a better handle on market dynamics and develop some consistency in meeting or beating expectations. Truist updated the company’s model to reflect the “slashed guidance and increased costs.” It now projects fiscal 2025 revenue of $211M for Amtagvi and $62M for Proleukin, totaling $272M, down from a prior $433M estimate.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics price target lowered to $4 from $5 at Barclays
- Iovance Biotherapeutics’ Earnings Call: Mixed Sentiments and Future Prospects
- Qualcomm initiated, Lyft upgraded: Wall Street’s top analyst calls
- Iovance Biotherapeutics price target lowered to $5 from $10 at TD Cowen
- Iovance Biotherapeutics price target lowered to $25 from $30 at Chardan